PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.97%
EBIT growth 75-90% of GNPX's 21.49%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
17.97%
Operating income growth at 75-90% of GNPX's 21.49%. Bill Ackman would demand a plan to enhance operating leverage.
18.43%
Net income growth at 75-90% of GNPX's 21.43%. Bill Ackman would press for improvements to catch or surpass competitor performance.
58.16%
EPS growth above 1.5x GNPX's 37.89%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
58.16%
Diluted EPS growth above 1.5x GNPX's 37.89%. David Dodd would see if there's a robust moat protecting these shareholder gains.
96.23%
Share count expansion well above GNPX's 26.50%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
96.23%
Diluted share count expanding well above GNPX's 26.49%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.94%
Similar OCF growth to GNPX's 22.29%. Walter Schloss would assume comparable operations or industry factors.
22.94%
FCF growth similar to GNPX's 24.34%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-567.72%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.81%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
89.23%
Positive 3Y OCF/share CAGR while GNPX is negative. John Neff might see a big short-term edge in operational efficiency.
-636.46%
Negative 10Y net income/share CAGR while GNPX is at 87.20%. Joel Greenblatt sees a major red flag in long-term profit erosion.
93.35%
5Y net income/share CAGR similar to GNPX's 87.20%. Walter Schloss might see both on parallel mid-term trajectories.
88.82%
Positive short-term CAGR while GNPX is negative. John Neff would see a clear advantage in near-term profit trajectory.
2271.09%
Equity/share CAGR of 2271.09% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-76.58%
Negative 5Y equity/share growth while GNPX is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-2.44%
Negative 3Y equity/share growth while GNPX is at 898.21%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
569.03%
Asset growth above 1.5x GNPX's 0.44%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
756.79%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
-16.19%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-15.49%
Our R&D shrinks while GNPX invests at 45.86%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-24.67%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.